Anti-Aging drug and football drills join forces to fight brittle bones

NCT ID NCT06789900

Ongoing Prevention Sponsor: Odense University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a weekly dose of everolimus (a drug that targets aging pathways) and/or a fun exercise program called 'Football Fitness' can prevent the rapid bone loss that happens after menopause. 136 healthy women aged 45-60 will be assigned to one of four groups: exercise only, drug only, both, or general health advice. The main goal is to see if these interventions improve bone formation markers after 24 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Everolimus (a rapamycin analog) and/or structured exercise training
What this could lead to: If successful, this could point toward a drug-and-exercise strategy to prevent postmenopausal bone loss and reduce fracture risk.
What could go wrong: This is a small, early-phase trial (136 women) testing bone marker changes, not fractures. Everolimus is an immunosuppressant with side effects, and benefits may not translate to real-world fracture prevention.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POSTMENOPAUSAL WOMEN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Bone Diseases, Metabolic Motor Activity postmenopausal osteoporosis prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

POSTMENOPAUSAL WOMEN

Contacts and locations

Locations

Odense University Hospital

Odense, 5000, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.